某院注射用曲妥珠单抗纳入医保目录前后使用情况分析

Analysis of the use of trastuzumab before and after inclusion in the medical insurance catalogue in a hospital

目的 了解注射用曲妥珠单抗纳入医保目录前后使用情况,为临床合理用药提供参考.方法 选取2016年9月1日~2018年8月31日使用注射用曲妥珠单抗的出院患者,分析纳入医保目录前后患者使用占比、指征、疗程及病史记录等情况.结果 纳入医保前后,住院患者使用注射用曲妥珠单抗人数分别为54例、142例;使用疗程大于8周期分别为7例、43例;病理记录完整的分别为22例、58例.结论 注射用曲妥珠单抗纳入医保目录后,减轻了使用该类药物患者的经济负担,惠及了肿瘤患者对该药物的可及性.

Objective To understand the use of trastuzumab infusion before and after inclusion in the medical insurance catalogue in our hospital,and to provide reference for clinical rational drug use.Methods The hospitalized patients who received trastuzumab for injection from September 1,2016 to August 31,2018 were selected to analyze the proportion,indications,course of treatment and medical history of patients before and after the trastuzumab inclusion in the medical insurance catalogue.Results Before and after enrollment in the medical insurance,the number of in-patients using trastuzumab was 54 and 142,respectively.The use of treatments was greater than 8 cycles in 7 and 43 cases respectively.The complete pathological records were 22 casesand 58 cases respectively.Conclusion After the injection of trastuzumab included in the medical insurance,it reduces the economic burden of patients,promotes the use of drugs in patients with tumors,and promotes standardized diagnosis and treatment of tumors.